Articles by Emily Menendez
Radium 223 is recommended for patients with symptomatic bone-only disease.
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Patients with ARPI-treated mCSPC and BRCA1/2 alterations experienced higher rates of disease progression.
Global shortages of BCG have led to the exploration of alternative therapies for HR non-muscle invasive bladder cancer.
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Hemi-gland cryoablation and HIFU provided acceptable and eminent functional outcomes in patients over a 5-year follow-up.
Patients with ccRCC and nccRCC with tumor thrombus have similar survival outcomes after surgical resection.
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging.
At the time of a pre-specified interim analysis, significant improvements in EFS and OS were seen.
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Surgical resection of the primary tumor can provide survival benefits in certain patients with metastatic UTUC.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.